Application of neo-bioscore staging to predict the benefit of pertuzumab in HER2 positive early breast cancer

被引：0
|
作者：
Sanchez Escudero, L. [1 ]
Morales Pancorbo, D. [2 ]
Bayo, J. [3 ]
Aragon Manrique, I. [3 ]
机构：
[1] Hosp Juan Ramon Jimenez, Oncol, Huelva, Spain
[2] Hosp Juan Ramon Jimenez, Med, Huelva, Spain
[3] Hosp Juan Ramon Jimenez, Oncol Med, Huelva, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
197P
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [1] Combined role of the neutrophil/lymphocyte ratio and Neo-Bioscore in neoadjuvant therapy in HER2-positive early breast cancer
    Sanchez Escudero, Laura
    Cobelas Cartagena, Stephanie S.
    Morales Pancorbo, David
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
    Zhao, Yingying
    Chen, Xinru
    Wang, Yaohui
    Zhang, Xueqing
    Lu, Jingsong
    Yin, Wenjin
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
  • [3] Validation of CPS plus EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China
    Xu, Ling
    Zhang, Zhuo
    Liu, Qianxin
    Zhou, Bin
    Liu, Yinhua
    Xiang, Qian
    Zhu, Sainan
    Duan, Xuening
    Cui, Yimin
    THORACIC CANCER, 2018, 9 (11) : 1565 - 1572
  • [4] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
  • [5] The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy Incorporation of Prognostic Biologic Factors Into Staging After Treatment
    Mittendorf, Elizabeth A.
    Vila, Jose
    Tucker, Susan L.
    Chavez-MacGregor, Mariana
    Smith, Benjamin D.
    Symmans, Fraser
    Sahin, Aysegul A.
    Hortobagyi, Gabriel N.
    Hunt, Kelly K.
    JAMA ONCOLOGY, 2016, 2 (07) : 929 - 936
  • [6] Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
    Steenbruggen, Tessa G.
    van Seijen, Maartje
    Janssen, LiseloreM.
    van Ramshorst, Mette S.
    van Werkhoven, Erik
    Peeters, Marie-Jeanne T. D. F. Vrancken
    Wesseling, Jelle
    Lips, Esther H.
    Sonke, Gabe S.
    CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4985 - 4992
  • [7] EARLY RELAPSE OF HER2 POSITIVE BREAST CANCER
    Zelen, Teodora Brdar
    Prica, Anja
    Jovisevic, Marija
    BREAST, 2023, 71 : S58 - S58
  • [8] Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
    Li, Jie
    Ma, Maoguang
    Yang, Xuesong
    Zhang, Maolei
    Luo, Jingyan
    Zhou, Huangkai
    Huang, Nunu
    Xiao, Feizhe
    Lai, Bingquan
    Lv, Weiming
    Zhang, Nu
    MOLECULAR CANCER, 2020, 19 (01)
  • [9] Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
    Jie Li
    Maoguang Ma
    Xuesong Yang
    Maolei Zhang
    Jingyan Luo
    Huangkai Zhou
    Nunu Huang
    Feizhe Xiao
    Bingquan Lai
    Weiming Lv
    Nu Zhang
    Molecular Cancer, 19
  • [10] Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
    Arriola, Edurne
    Rodriguez-Pinilla, Socorro Maria
    Lambros, Maryou B. K.
    Jones, Robin L.
    James, Michelle
    Savage, Kay
    Smith, Ian E.
    Dowsett, Mitch
    Reis-Filho, Jorge S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (02) : 181 - 189
12345